Pemetrexed in combination with cisplatin in the first-linetreatment of non-squamous NSCLC: Czech experience with 233patients
2013
In a group of 233 patients with advanced non-squamous NSCLC who
were treated with pemetrexed in first line and in combination
with cisplatin, the therapy was well tolerated: termination of
treatment due to adverse events was reported only in 3.8% of
patients. Median overall was 11.6 months, median
progression-free survival was 4.2 months.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI